Abstract
Supraphysiological hormonal profiles are the cause of luteal defect observed in stimulated IVF cycles. Hence it is essential to support the luteal phase in stimulated cycles for which different forms of support are available. Progesterone and human chorionic gonadotropins (hCGs) so far have been the ideal supports for pregnancy. HCG results in higher incidence of ovarian hyperstimulation. Luteal phase support with progesterone results in increase in implantation and pregnancy rates. For now, progesterone seems to be the best option as luteal phase support. Oral progesterone is associated with reduced bioavailablity. Vaginal progesterone is associated with increased at-site concentration.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zhao Y, Zacur H, Cheadle C, Ning N, Fan J, Vlahos NF. Effect of luteal-phase support on endometrial microRNA expression following controlled ovarian stimulation. Reprod Biol Endocrinol. 2012;6(10):72.
Miyake A, Aono T, Kinugasa T, Tanizawa O, Kurachi K. Suppression of serum levels of luteinizing hormone by short- and long-loop negative feedback in ovariectomized women. J Endocrinol. 1979;80(3):353–6.
Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003;14(5):236–42.
Jones GS. Luteal phase defect: a review of pathophysiology. Curr Opin Obstet Gynecol. 1991;3(5):641–8.
Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003;88(9):4186–92.
Bulletti C, de Ziegler D. Uterine contractility and embryo implantation. Curr Opin Obstet Gynecol. 2006;18(4):473–84. Review.
Kleinstein J. Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertil Steril. 2005;83(6):1641–9.
Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomized study. J Steroid Biochem Mol Biol. 2005;97(5):416–20.
Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002;17:2287–99.
Cicinelli E, Schonauer LM, Galantino P, Matteo MG, Cassetta R, Pinto V. Mechanisms of uterine specificity of vaginal progesterone. Hum Reprod. 2000;15 Suppl 1:159–65.
de Ziegler D, Seidler L, Scharer E, Bouchard P. Non-oral administration of progesterone: experiences and possibilities of the transvaginal route. Schweiz Rundsch Med Prax. 1995;84(5):127–33.
Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril. 2009;92(1):163–9.
Ludwig M, Schwartz P, Babahan B, Katalinic A, Weiss JM, Felberbaum R, Al-Hasani S, Diedrich K. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol. 2002;103(1):48–52.
Honda T, Fujiwara H, Yamada S, Fujita K, Nakamura K, Nakayama T, et al. Integrin a5 is expressed on human luteinizing granulosa cells during corpus luteum formation, and its expression is enhanced by human chorionic gonadotrophin in vitro. Mol Hum Reprod. 1997;3(11):979–84.
Buvat J, Marcolin G, Guittard C, Dehaene JL, Herbaut JC, Louvet AL. [Luteal support after administration of an LHRH analog for in vitro fertilization]. Superiority of vaginal progesterone in comparison with oral progesterone. Presse Med. 1990;19(11):527.
Araujo Jr E, Bernardini L, Frederick JL, Asch RH, Balmaceda JP. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction. J Assist Reprod Genet. 1994;11(2):74–8.
van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011;(10):CD009154. doi:10.1002/14651858.CD009154.pub2.
Kolibianakis EM, Venetis CA, Papanikolaou EG, Diedrich K, Tarlatzis BC. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadotrophins for IVF: a systematic review and meta-analysis. Hum Reprod. 2008;23(6):1346–54.
Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril. 2008;90(6):2116–25.
Bueno MJ, Pérez de Castro I, Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle. 2008;7(20):3143–8.
Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006;21(10):2572–9.
Oliveira JB, Baruffi R, Petersen CG, Mauri AL, Cavagna M, Franco Jr JG. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol. 2010;8:107.
Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(6):734–40.
Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod. 2005;20(7):1798–804.
Griesinger G, Franke K, Kinast C, Kutzelnigg A, Riedinger S, Kulin S, et al. Ascorbic acid supplement during luteal phase in IVF. J Assist Reprod Genet. 2002;19(4):164–8.
Ubaldi F, Rienzi L, Ferrero S, Anniballo R, Iacobelli M, Cobellis L, Greco E. Low dose prednisolone administration in routine ICSI patients does not improve pregnancy and implantation rates. Hum Reprod. 2002;17(6):1544–7.
Okuda K, Miyamoto Y, Skarzynski DJ. Regulation of endometrial prostaglandin F(2alpha) synthesis during luteolysis and early pregnancy in cattle. Domest Anim Endocrinol. 2002;23(1–2):255–64.
Wada I, Hsu CC, Williams G, Macnamee MC, Brinsden PR. The benefits of low-dose aspirin therapy in women with impaired uterine perfusion during assisted conception. Hum Reprod. 1994;9(10):1954–7.
Hurst BS, Bhojwani JT, Marshburn PB, Papadakis MA, Loeb TA, Matthews ML. Low-dose aspirin does not improve ovarian stimulation, endometrial response, or pregnancy rates for in vitro fertilization. J Exp Clin Assist Reprod. 2005;2:8.
Geva E, Amit A, Lerner-Geva L, Yaron Y, Daniel Y, Schwartz T, et al. Prednisone and aspirin improve pregnancy rate in patients with reproductive failure and autoimmune antibodies: a prospective study. Am J Reprod Immunol. 2000;43(1):36–40.
Takasaki A, Tamura H, Taniguchi K, Asada H, Taketani T, Matsuoka A, et al. Luteal blood flow and luteal function. J Ovarian Res. 2009;2:1.
Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril. 2002;78(5):1073–6.
Baruffi R, Mauri AL, Petersen CG, Felipe V, Franco Jr JG. Effects of vaginal progesterone administration starting on the day of oocyte retrieval on pregnancy rates. J Assist Reprod Genet. 2003;20(12):517–20.
Mochtar MH, Van Wely M, Van der Veen F. Timing luteal phase support in GnRH agonist down-regulated IVF/embryo transfer cycles. Hum Reprod. 2006;21(4):905–8.
Schmidt KL, Ziebe S, Popovic B, Lindhard A, Loft A, Andersen AN. Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate. Fertil Steril. 2001;75(2):337–41.
Nyboe AA, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A, Ziebe S, Hald F, Hauge B, Toft B. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod. 2002;17(2):357–61.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer India
About this chapter
Cite this chapter
Talwar, S. (2015). Luteal Support: What to Use When?. In: Ghumman, S. (eds) Principles and Practice of Controlled Ovarian Stimulation in ART. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1686-5_22
Download citation
DOI: https://doi.org/10.1007/978-81-322-1686-5_22
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-1685-8
Online ISBN: 978-81-322-1686-5
eBook Packages: MedicineMedicine (R0)